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Running title: Deoxysphingolipids cause HSAN1 
 
Abstract: 
HSAN1 is an inherited neuropathy 
found to be associated with several 
missense mutations in the SPTLC1 
subunit of serine palmitoyltransferase 
(SPT). SPT catalyzes the condensation 
of serine and palmitoyl-CoA, the initial 
step in the de novo synthesis of 
sphingolipids. Here we show that the 
HSAN1 mutations induce a shift in the 
substrate specificity of SPT which leads 
to the formation of the two atypical 
deoxy-sphingoid bases (DSB) 1-deoxy-
sphinganine and 1-deoxymethyl-
sphinganine. Both metabolites lack the 
C1 hydroxyl group of sphinganine, and 
can therefore neither be converted to 
complex sphingolipids nor degraded. 
Consequently, they accumulate in the 
cell, as demonstrated in HEK293 cells 
overexpressing mutant SPTLC1 and 
lymphoblasts of HSAN1 patients. 
Elevated DSB levels were also found in 
the plasma of HSAN1 patients, and 
confirmed in three groups of HSAN1 
patients with different 
SPTLC1mutations. The DSBs show 
pronounced neurotoxic effects on 
neurite formation in cultured sensory 
neurons. The neurotoxicity co-occurs 
with a disturbed neurofilament 
structure in neurites when cultured in 
the presence of DSBs. Based on these 
observations we conclude that HSAN1 is 
caused by a gain of function mutation, 
which results in the formation of two 
atypical and neurotoxic sphingolipid 
metabolites. 
 
Introduction: 
Hereditary sensory and autonomic 
neuropathy type 1 (HSN1 or HSAN1) is 
the most frequent HSAN subtype (1). It is 
an autosomal dominant condition, 
clinically characterized by loss of pain and 
temperature sensation in feet and hands, 
often accompanied by lancinating pain 
attacks, skin ulcers and infections (2). 
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Furthermore, degeneration of motor 
neurons frequently occurs accompanied by 
atrophy and weakness of distal limb 
muscles. Positional cloning identified 
mutations in the SPTLC1 gene (3,4), which 
encodes the first of the three subunits of 
serine palmitoyltransferase (SPT) (5,6). 
SPT catalyzes the pyridoxalphosphate 
(PLP) dependent condensation of L-serine 
and palmitoyl-CoenzymeA (Palm-CoA), 
the first and rate-limiting step in the de 
novo synthesis of sphingolipids (7) 
(Fig.1A) 
Four missense mutations (C133W, C133Y, 
V144D and G387A) in SPTLC1 have been 
reported in a total of 24 HSAN1 families. 
C133W is the most frequent mutation, 
found in 18 HSAN1 families (3,4,8-10), 
whereas C133Y was reported in three 
(3,4,11), and V144D in two families (3). 
The G387A mutation was described in one 
family (12) but is not disease causing (13). 
Recently two further mutations in SPTLC1 
were reported to be associated with 
HSAN1(14). In vitro activity of the 
C133W and C133Y mutants is reduced in 
various cell types, including lymphocytes 
cultured from HSAN1 patients (15-17). 
HSAN1 is therefore commonly believed to 
be caused by a loss of SPT function. 
Following this reasoning, 
haploinsufficency should be reflected in 
reduced total sphingolipid levels. This, 
however, could not be confirmed in 
HSAN1. Dawkins et al. initially reported 
increased glucosylceramide levels in 
HSAN1 patients (3) whereas others found 
no changes in the lipid composition (16). 
Also transgenic SPTLC1C133W mice 
showed significantly decreased SPT 
activity but no reduction in total 
sphingolipid levels (18). Nevertheless, 
these mice developed an age-dependent 
peripheral neuropathy with motor and 
sensory impairments (18). The hypothesis 
that HSAN1 is caused by 
haploinsufficiency is further challenged by 
the observation that heterozygous SPTLC1 
and SPTLC2 knockout mice, which have a 
significantly reduced SPT activity, do not 
develop neuropathic symptoms (19). 
Here, we demonstrate that the HSAN1 
mutations in SPT lead to a shift in 
substrate specificity of the enzyme which 
then forms two atypical and neurotoxic 
deoxy-sphingoid bases (DSB). Our 
findings therefore suggest that the 
pathological mechanism in HSAN1 is the 
accumulation of these neurotoxic 
metabolites rather than the reduced de 
novo sphingolipid synthesis. This gain of 
function concept is also consistent with the 
dominant mode of inheritance in HSAN1. 
Experimental procedures: 
Patients 
Approval to perform this study was 
obtained from the The National Hospital 
for Neurology and Neurosurgery and 
Institute of Neurology Joint Research 
Ethics Committee (Queen Square, London) 
and the Institutional Review Board 
(Massachusetts General Hospital, Boston, 
MA). Plasma from blood samples were 
obtained after informed consent from 
affected individuals. 
Cell culture: 
HEK293 cells were obtained from ATCC 
and cultured in Dulbecco’s modified 
Eagle’s medium (Sigma) with 10 % fetal 
calf serum (Fisher scientific FSA15-043) 
and Penicillin/Streptomycin (100 units per 
ml/0.1 mg per ml, Sigma). 
EBV transformed lymphoblast cell lines 
were cultured in RPMI 1640 media 
(Sigma) supplemented with 15 % fetal calf 
serum (Fisher scientific FSA15-043), 
Penicillin/Streptomycin (100 units per 
ml/0.1 mg per ml, Sigma), 2 mM L-
glutamine, 1 mM sodium pyruvate, 
0.075% sodiumbicarbonate and 1 mM 
HEPES. 
Statistics: 
Significance levels were determined with 
an unpaired student t-test using Sigma Plot 
v10.0 (SystatSoftware, Inc.). P-values 
 0.05 were labelled with “*” and  0.01 
with “**”. 
DRG neuron cultures  
Sensory neurons of dorsal root ganglia and 
motoneurons were cultured as single cells 
essentially as described previously (20). In 
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brief, DRG were dissected from chicken 
embryos at day 8 (motoneurons at day 6) 
and cultured for 12 hours in serum-free 
medium before the lipids were added as a 
BSA complex at the concentrations 
indicated in the text. The lipid-BSA stock 
solution was prepared from a 50mM lipid 
ethanol stock (SA, m18:0 and m17:0 were 
obtained from Avanti Polar Lipids) by the 
dropwise dilution of the lipids into PBS 
containing 0.4% BSA until a final 
concentration of 1mM. After 24 hours, 
cells were fixed by the addition of 
paraformaldehyde to the culture medium at 
a final concentration of 4%. Neurites were 
visualized by neurofilament staining with 
RMO270 (1:1500) and donkey anti-mouse 
IgG-Cy3 (1:500). Neurons were classified 
according to the number of neurites into 4 
classes (no neurite, one neurite, 2 neurites, 
>2 neurites/cell). The total neurite length 
per cell was measured and the distribution 
of neurite lengths was represented as 
percentage of neurons with a total neurite 
length longer than x (Chang plot) (21). 
Cloning: 
SPTLC1 cDNA was cloned into a 
pcDNA3.1 expression vector and 
expressed in HEK293 cells as described 
previously(6). The C133W and C133Y 
mutation was introduced using site directed 
mutagenesis  
C133fw: 5`-
ggggacccagaggattttatggcacatttgatgttc-3`; 
C133Yfw: 5`-
atggtcctcgaggattttatggcacatttgatgttc-3`; 
C133W+C133Yrv: 5`-
aggtacccacgccatacttctttagagatgctaaagc-3`  
Fumonisin B1 dependent accumulation 
of sphingoid bases 
Fumonisin B1 (Sigma) was added to the 
media of exponentially growing cells in a 
final concentration of 10 µg/ml. As a 
negative control myriocin (10 µg/ml, 
Sigma) was added together with Fumonisin 
B1. 24 hours after Fumonisin B1 addition, 
cells were washed twice with PBS, 
harvested and counted (coutler® Z2, 
Beckman Coulter). Synthetic C17 
sphingosine (Avanti Polar Lipids) was 
added to each sample as an internal 
extraction standard. 
Lipid extraction and hydrolysis 
Total lipids were extracted from cells or 
plasma and extracted according to the 
method of Riley et al. (22). The extracts 
were base - or acid and base hydrolyzed as 
stated in the text. Before extraction, cells 
were resuspended in 200 µl PBS and 
plasma samples (human 100 µl, mice 50 
µl) were filled up to a volume of 200 µl 
with PBS. Briefly, lipids were extracted in 
1ml extraction buffer 1 (2 vol. methanol/1 
vol. chloroform + 0.2 µl/ml C17 SO (1mM 
in EtOH). 100 µl of ammonia (2N) was 
added and the lipids extracted under 
constant agitation (1h, 37 °C). 
Subsequently 0.5 ml chloroform was added 
and samples were centrifuged (12,000 g, 5 
min) to separate the organic from the water 
phase. The upper (water) phase was 
removed and the lower phase washed twice 
with 1ml of alkaline water (1ml ammonia 
(2M) in 100ml water) and dried under N2. 
For acid hydrolysis, the dried lipids were 
resupended in 200 µl methanolic HCl (1 N 
HCl/10 M water in methanol) and kept at 
65 °C for 12-15 hours. The solution was 
neutralized by the addition of 40 µl KOH 
(5 M) and subsequently subjected to base 
hydrolysis. 
Base hydrolysis was performed as 
followed: 0.5 ml extraction buffer (4 vol. 
0.125 M KOH in methanol + 1 vol. 
chloroform) was added and mixed. 
Subsequently, 0.5 ml chloroform, 0.5 ml 
alkaline water and 100 µl 2M ammonia 
was added in this order. Liquid phases 
were separated by centrifugation (12,000 g, 
5 min). The upper phase was aspirated and 
the lower phase washed twice with alkaline 
water. Finally, the lipids were dried by 
evaporation of the chloroform phase under 
N2 and subjected to LC-MS analysis.  
LC-MS 
Extracted lipids were solubilized in 56,7% 
methanol/33.3% ethanol/10% water and 
derivatized with ortho-phthaldialdehyd 
(OPA, Sigma) (22). The lipids were 
separated on a C18 column (Uptispere 
120Å, 5µm, 125x2mm, Interchim, France) 
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and analyzed by a serial arrangement of a 
fluorescence detector (HP1046A, Hewlet 
Packard) followed by a MS detector 
(LCMS-2010A, Shimadzu). APCI 
(atmospheric pressure chemical ionisation) 
was used for ionisation. Non natural C17 
sphingosine (Avanti Polar Lipids) was 
used as internal standard. Retention times 
were as following: C17SO (int.STD)-6min; 
SO-7.5min; m18:1- 9min; m17:1-10.5min; 
SA-10.5min, m17:0 -13min; m18:0 -
13.5min 
MS data were analysed using LCMS 
solution (Shimadzu) and MS Processor 
v.11 (ACD Labs). The quantified lipids 
were normalized for cell number (per 
million cells) and the internal standard. 
Results: 
To test the hypothesis that a gain of 
function rather than a loss of function 
underlies the pathology in HSAN1, we 
generated HEK293 (HEK) cell lines 
expressing either the SPTLC1 wildtype 
subunit (HEKL1), the SPTLC1 mutants 
C133W and C133Y (HEKC133W, 
HEKC133Y) or the vector alone (HEKempty). 
All constructs were expressed at similar 
levels without any sign of protein 
degradation (Suppl. Fig.1A). Over-
expression of the SPTLC1 wildtype 
subunit had no influence on SPT activity 
(Suppl. Fig.1B), whereas cells expressing 
the HSAN1 show a 50% reduced SPT 
activity in vitro, as reported previously 
(15-17) (Suppl. Fig.1B). 
 
Mutant forms of SPT generate an atypical 
metabolite 
To detect possible side products of the SPT 
reaction we blocked the sphingolipid de 
novo synthesis at the step of ceramide 
synthase (CerS) with Fumonisin B1 (FB1) 
(Fig. 1A). The inhibition of CerS leads to a 
time dependent accumulation of its 
substrate sphinganine (SA) (Suppl.Fig.1C). 
Hence it was assumed that potential side 
products of the SPT reaction would also 
accumulate under these conditions. The 
addition of FB1 showed no negative effect 
on cell survival within the given time 
window (Suppl. Fig.1C). After 24 hours, 
the accumulated lipids were extracted, 
separated, and quantified by HPLC (22).  
The addition of FB1 led to a significant 
accumulation of sphinganine (Fig.1B), 
whereas no accumulation was seen when 
SPT activity was blocked with myriocin. 
SA generation was about 50% reduced in 
HEKC133W cells due to the lower activity of 
the mutant SPT. Concomitantly we 
observed the appearance of a second peak 
(Fig.1B). The accumulation of this 
unknown metabolite was significantly 
higher in HEKC133W cells than in HEKL1 
cells. The peak was also increased in 
HEKC133Y cells but was not observed when 
SPT activity was blocked with myriocin. 
This indicates that the unknown metabolite 
is a product of the SPT reaction. 
 
HSAN1 mutations induce a shift in SPT 
substrate specificity 
For further characterization, we compared 
lipid extracts of FB1 treated HEKC133W 
cells with those of HEKempty and HEKL1 
cells by LC-MS. The analysis revealed the 
presence of two distinct metabolites which 
were merged and appeared as a single peak 
in the fluorescence chromatogram. The 
two metabolites had a mass to charge ratio 
(m/z) of 462.3 and 448.3, respectively 
(Suppl. Fig.1D). Hence, these metabolites 
were 16 and 30 Da smaller in mass than 
SA (m/z = 478.3). This corresponds to the 
masses of oxygen (16 Da) and a 
hydroxymethyl group (-CHOH; 30 Da), 
respectively. SA contains two hydroxyl 
groups, one at C3 that derives from the 
fatty acid moiety and a second at C1 that 
originates from the conjugated serine. 
Strikingly, the mass of serine differs from 
that of alanine and glycine by 16 and 30 
Da, respectively. We therefore assumed 
that the two identified metabolites 
originated from the conjugation of Palm-
CoA with alanine and glycine instead of 
serine. This reaction would result in two 
atypical sphingolipids, deoxy-sphinganine 
(m18:0, deoxy-SA) and deoxymethyl-
sphinganine (m17:0, deoxymethyl-SA) 
(Fig.2A and B). A shared feature of these 
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sphingoid bases is the lack of the C1 
hydroxyl group which assigns them to the 
class of deoxy-sphingoid bases (DSBs). 
To confirm this hypothesis, cultured 
HEKC133W cells were supplemented with 
either alanine (10mM) or glycine (10mM). 
Sphingolipid de novo synthesis was 
blocked with FB1 for 24h and the 
accumulated lipids analyzed by LC-MS 
(Fig.2C). The addition of alanine to the 
medium provoked an approximately 3 to 4-
fold increase of m18:0 without 
significantly influencing the m17:0 levels. 
Conversely, the addition of glycine 
induced a ten-fold increase of m17:0. The 
slight increase in SA, seen with the glycine 
supplemented cells, is probably due to a 
partial, intracellular conversion of glycine 
to serine which then, secondarily, 
stimulates the generation of SA (d18:0). 
This confirms that the HSAN1 mutations 
induce a shift in the substrate affinity of 
SPT from serine towards alanine and 
glycine. 
Among the mutants we observed a 4-5 fold 
higher accumulation of m18:0 in 
HEKC133W and HEKC133Y cells compared to 
HEKempty or HEKL1 cells (Fig.2D). This 
shows that the affinity towards alanine is 
greatly increased for the HSAN1 mutants. 
The differences between wildtype and 
mutants was even more pronounced for the 
accumulation of 1-deoxymethyl-
sphinganine (m17:0) which was only 
detected in the mutant but not in the 
wildtype expressing cells. HEKC133Y cells 
produced, in comparison to HEKC133W, 
about 25% and 60% lower levels of m18:0 
and m17:0, respectively. 
Interestingly, low levels of m18:0, but not 
of m17:0, were also detected in HEK 
wildtype and HEKL1 cells (Fig.2D). This 
suggests that the wildtype SPT is also able 
to metabolize alanine however to a much 
lesser extent than the HSAN1 mutants. The 
amount of accumulated m18:0 in HEK 
wildtype and HEKL1 cells was about 5-fold 
lower than the levels observed in 
HEKC133W or HEKC133Y cells. 
 
Increased DSB generation in lymphoblasts 
of HSAN1 patients 
The over-expression of mutant SPTLC1 in 
the background of two wild-type alleles 
does not necessarily represent the situation 
in HSAN1 patients in which the mutant 
and wildtype alleles are present in 
equivalent doses. We therefore sought to 
confirm our findings by comparing EBV 
transformed lymphoblast lines of HSAN1 
patients and healthy controls. All HSAN1 
cells were derived from C133W carriers. 
C133Y lymphoblasts were not available. In 
FB1 treated lymphoblasts from HSAN1 
patients, but not in lymphoblasts from 
healthy controls, we observed a significant 
accumulation of m18:0 and m17:0 
(Fig.3A). SA levels were not significantly 
different between patient and control cells. 
No accumulation was seen when the cells 
were grown in the presence of myriocin. 
Although all HSAN1 cells showed 
consistently elevated DSB levels, the 
absolute accumulation of m17:0 and m18:0 
varied considerably between the different 
patient lines. Since all cells were cultured 
under identical conditions this 
heterogeneity could either reflect the 
variable genetic background of the patients 
or might be a consequence of the previous 
EBV transformation. 
 
DSB accumulated in HSAN1 lymphoblasts 
The lack of the C1 hydroxyl group in the 
DSBs has consequences for the 
metabolism of these lipids. Due to the 
absence of the hydroxyl group the DSBs 
cannot be converted to higher substituted 
sphingolipids, like phospho- and 
glycosphingolipids, but also not degraded 
by the classical pathway since this requires 
the formation of a phosphoester bond at C1 
(Fig.1A). Nevertheless, the DSBs serve as 
a substrate for CerS as shown previously 
by testing the effect of several synthetic 
sphingoid base analogs (23). The DSBs are 
N-acylated and also desaturated by 
ceramide desaturase (DES), which results 
in the formation of deoxy-ceramide and 
deoxymethyl-ceramide. The release of the 
N-linked acyl chain by ceramidase then 
 5
results in the formation of deoxy-SO 
(m18:1) and deoxymethyl-SO (m17:1), 
respectively. To confirm the metabolic fate 
of the DSBs, we analyzed the sphingoid 
base composition in lipid extracts of 
HSAN1 lymphoblasts. For this we 
subjected the extracted lipids to an acid 
and base hydrolysis. The acid hydrolysis 
specifically breaks the N-alkyl chain 
whereas the basic hydrolysis leads to a 
release of the O-linked phosphoester or 
carbohydrate head group. A combined 
acid/base hydrolysis reveals, therefore, the 
total sphingoid base contents in a cell. The 
lipid extracts of HSAN1 lymphoblasts 
lines showed significantly higher DSB 
levels compared to control cells (Fig.3B). 
The levels of saturated (m18:0, m17:0) 
significantly increased, whereas SA 
(d18:0) and SO (d18:1) levels were not 
different between control and HSAN1 
cells. This confirms earlier reports that the 
HSAN1 cells are able to maintain normal 
SA and SO levels despite the reduced SPT 
activity (16). Besides the saturated, also 
the unsaturated DSBs (m18:1, m17:1) were 
significantly increased in HSAN1 
lymphoblast. Although standards for 
m18:1 and m17:1 are commercially not 
available the metabolites were identified 
according to their mass difference of 2 Da 
and their correlation to their precursors 
m17:0 and m18:0 (Suppl. Fig.1E) 
Among the d18 sphingoid bases d18:1 
(SO) was the most prominent. A d18:0 
(SA) backbone was found in about 10% of 
the d18 sphingoid bases which shows that 
the majority of the de novo generated SA 
is metabolized to ceramide. This is 
different for the DSBs. About 80% of the 
m18 bases in the lymphoblast were found 
in the saturated form (m18:0). In contrast 
m17:0 and m17:1 were present in equal 
levels. The disproportion between m18:0 
and m18:1 was also observed in HEKC133W 
cells whereas m17 bases were only present 
as m17:1 (Suppl.Fig.2). The higher levels 
of saturated over unsaturated DSBs 
indicates that m18:0 is a less favorable 
substrates for the ceramide-desaturase 
(DES) than SA (d18:0). 
 
DSB levels are elevated in the plasma of 
HSAN1 patients 
To confirm these in vitro results, we 
analyzed DSB levels in the plasma of three 
different sets of HSAN1 patients. The first 
set consisted of seven C133W carriers 
from three unrelated families and three 
unrelated non-carriers (Fig.4A, B). The 
second set included ten carriers and ten 
non-carriers from one single C133Y family 
(Fig.4C). A third set consisted of three 
unrelated V144D carriers and four 
unrelated non-carriers (Fig.4D). The 
plasma samples were subjected to 
acid/base hydrolysis and the DSB levels 
analyzed by LC-MS. For all C133W 
carriers the levels of the m18 and m17 
sphingoidbases were significantly elevated 
(Fig.4A and B). All HSAN1 samples (P1-
7) showed elevated levels for m18:0 and 
m18:1 bases compared to controls (C1-7). 
In most patients m18:1 was more abundant 
than m18:0. Minor amounts of m18:0 and 
m18:1 were also detected in the plasma of 
control subjects whereas m17:0 and m17:1 
was only found in the patients. In plasma 
we found generally higher proportions of 
unsaturated (m17:1 and m18:1) than 
saturated (m17:0, m18:0) DSBs. The 
highest DSB levels were seen in patient 7, 
who also presented the most severe 
HSAN1 phenotype in this collective. One 
patient (Pat.3) developed a severe form of 
the disease but had only intermediately 
elevated DSB levels. This outlier can 
possibly be explained by a history of 
alcohol abuse in this patient that could 
have accelerated the neuropathic 
symptoms. The other patients were 
moderately affected and showed 
moderately elevated DSB levels. 
The analysis of a C133Y family gave 
similar results (Fig.4C), with the exception 
that in these patients the m17 bases were 
below the detection limit. This indicates 
that the C133Y mutant has a lower affinity 
for glycine compared to the C133W 
mutation, which is also reflected in a lower 
m17:0 generation in HEKC133Y cells 
compared to HEKC133W cells (Fig.2D). 
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Significantly elevated m18:0 and m18:1 
plasma levels were also found in patients 
with the V144D mutation (Fig.4D). This 
shows that the V144D mutation, although 
located at a different site of the protein, 
induces the same shift in substrate 
specificity as the C133W/Y mutations. As 
for the C133Y mutation the m17 sphingoid 
bases were below the detection limit in the 
plasma of the V144D patients. 
 
The DSBs impair neurite formation in 
culture 
To see whether the identified metabolites 
functionally affect the neuronal integrity 
we tested their effect on cultured dorsal 
root ganglia (DRG) neurons. DRGs were 
dissected, dissociated and cultured in 
serum-free medium for 12h prior the 
addition of the lipids. After another 24h of 
incubation, cells were fixed and stained for 
neurofilament to assess neurite outgrowth 
(Fig.5A). The addition of SA (1 µM) had 
no obvious effect on neurites in 
comparison to control cells where no lipids 
where added (BSA only). The addition of 
m18:0 (1 µM), however, resulted in a 
remarkable reduction of neurite numbers 
(Fig.5A). Also the addition of m17:0 (1 
µM) showed an effect on neurite 
formation, although this effect was less 
pronounced than with m18:0.  
The quantitative analysis confirmed these 
observations and revealed a dose-
dependent effect of m18:0 on neurite 
number and length (Fig.5B). About 30% of 
the control cells had one or more neurites 
per cell. This was unchanged when the 
cells were cultured in the presence of SA. 
In the presence of m18:0 (1µM), however, 
the number of cells with one or more 
neurites was significantly diminished 
(Fig.5B). The addition of m17:0 showed a 
milder effect and primarily reduced the 
number of cells with more than two 
neurites. Interestingly, the addition of 
m18:0 and m17:0 did not affect the number 
of viable neurons when compared to 
control (BSA only) or SA treated cells. 
This shows that up to a concentration of 
1µM, the DSBs do not induce cell death in 
cultured sensory neurons. Rather, it seems 
that the DSBs disturb specifically neurite 
formation in these neurons. 
Compared to sensory neurons motoneurons 
are reported to be less affected in HSAN1. 
We therefore tested whether motoneurons 
are less sensitive to the DSBs (Fig.5C). 
Also, motoneurons that were cultured in 
the presence of m18:0 showed an overall 
reduction in neurite numbers. However, 
this reduction was less pronounced than in 
sensory neurons (Fig.5B). Especially at 
higher concentrations of m18:0 (1µM) the 
proportion of cells with one or more 
neurites were clearly higher in moto- than 
in sensory neurons.  
The analysis of neurite length showed a 
concentration dependent effect of m18:0 
on the length of the formed neurites 
(Fig.5D). Low concentrations of m18:0 
(0.1µM) had no significant effect on 
neurite length in comparison to control 
conditions, e.g. no added lipids or 0.5-1µM 
SA. Higher m18:0 concentrations (0.5 and 
1µM) resulted in a significant and dose 
dependent reduction of neurite length. 
Remarkably, the highest tested 
concentration of m18:0 (1µM) not only 
prevented further neurite growth but 
seemed even to result in a net reduction of 
neurite lengths when compared to the 
length of the neurites before adding the 
lipids (Fig5D, dashed line). We therefore 
repeated this experiment on neurons which 
were pre-cultured for 24h before the lipids 
were added (Fig.5E). In control and SA (1 
µM) treated cells the neurites continued to 
grow over time, although the growth rate 
seemed to be slightly diminished in the 
presence of SA. In contrast, the addition of 
m18:0 resulted in a significant retraction of 
the already formed neurites with an 
increased percentage of neurites with less 
than 200µm length (Fig.5E). The analysis 
of the neurites by immune fluorescence 
microscopy showed a co-localization of 
actin and neurofilament over the whole 
length of the neurites in neurons which 
were cultured in the presence of SA 
(Fig.5F). In contrast, the neurites of 
neurons that were cultured in the presence 
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of m18:0 had a clearly disturbed 
cytoskeletal structure. The neurofilament 
staining was significantly shortened in 
these cells and only partly co-localized 
with the actin staining, whereas the actin 
signal was detected over the whole length 
of the neurites. This indicates that m18:0 
influences the stability and dynamics of 
neurofilament formation. 
In summary, our results demonstrate a 
neurotoxic effect of the alternative 
metabolites formed by the mutant forms of 
SPT. Thus, we conclude that the 
neuropathology in HSAN1 is due to the 
accumulation of these aberrant SPT 
products rather than haplotype 
insufficiency. 
Discussion: 
Various mutations in the SPTLC1 subunit 
of SPT cause HSAN1, a form of hereditary 
sensory and autonomic neuropathy. It has 
been repeatedly shown that these mutations 
result in reduced enzymatic activity. 
However, this reduced activity does not 
induce changes in total cellular 
sphingolipid levels (16). Also, our own 
analysis showed no significant differences 
between the total sphingolipid levels of 
lymphoblasts from HSAN1 patients and 
those from healthy controls (Fig.2B). 
Neither were total sphingoid base levels 
different in plasma from HSAN1 patients 
compared to healthy controls. This 
incongruous finding can be explained by 
the fact that cells can also generate 
ceramide by the degradation of 
sphingomyelin from external sources (24) 
and are, therefore, principally able to 
compensate for a reduced de novo 
ceramide synthesis. Furthermore, 
heterozygous SPTLC1 and SPTLC2 
knockout mice have significantly reduced 
SPT activity but do not develop 
neuropathic symptoms (19). Thus, a 
reduced SPT activity is not, by itself, a 
sufficient explanation for the pathogenesis 
in HSAN1. 
In this study, we demonstrated that the 
C133W and the C133Y mutations, which 
are the most frequent HSAN1 mutations, 
cause a shift in the substrate specificity of 
SPT. We showed that mutated SPT is able 
to use alanine and, to a lesser extent, 
glycine as alternative substrates. In 
consequence, the two sphingolipid 
metabolites 1-deoxy-sphinganine (deoxy-
SA, m18:0) and 1-deoxymethyl-
sphinganine (deoxymethyl-SA, m17:0) are 
formed, which both lack the hydroxyl 
group at C1. This prevents the further 
conversion of these metabolites to glyco- 
or phospho-sphingolipids but also impedes 
their degradation, which requires the 
phosphorylation at C1 and the subsequent 
breakdown by S1P-lyase (Fig.1A). 
Consequently, these metabolites were 
found in high concentrations in those cells 
that express the mutant SPT. Elevated 
deoxy-sphingoid base (DSB) levels were 
found in lymphoblasts of HSAN1 patients 
and plasma DSB levels were significantly 
elevated in HSAN1 patients, who carry 
either the C133W, C133Y or the V144D 
mutation. 
Elevated DSB levels were also found in 
plasma of mice which are transgenic for 
the SPTLC1C133W mutant as reported 
recently (25). Interestingly, double 
transgenic mice (dTG) which 
concomitantly overexpress the C133W 
mutant together with wildtype SPTLC1 do 
not develop neurological symptoms (25). 
This correlates with significantly lower 
DSB plasma levels in these mice. 
However, DSB levels in the dTG mice are 
still higher than in wt, SPTLC1wt 
overexpressing or heterozygous SPTLC1 
+/- KO mice suggesting that DSBs can be 
tolerated up to a certain threshold level. 
Tissue analysis revealed the presence of 
highly elevated DSB levels in the sciatic 
nerves of the C133W mice but not of wt 
mice (25). No differences in the DSB 
levels were seen in brain tissue of C133W 
and wt mice. This shows that the DSBs 
accumulate specifically in PNS but not in 
CNS tissue which fully corresponds to the 
pattern of pathology in HSAN1 as the CNS 
is not affected in this disease. 
Low amounts of m18 sphingoid bases, but 
not of m17 sphingoid bases, could be also 
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detected in control plasma and non-
HSAN1 cells. This indicates that also the 
wildtype SPT has a certain affinity towards 
alanine. Similar findings were reported 
recently by Riley and co-workers which 
demonstrated the accumulation of deoxy-
SA in FB1 treated LLC-PK1 cells (26). 
Structurally, deoxy-SA resembles the 
members of the fumonisin “B” series, 
whereas the glycine derivate shares a 
structural homology with the “C” series of 
fumonisins. These mycotoxins are formed 
in a variety of fungal species by the 
condensation of a polyketide chain to 
alanine or glycine which is catalyzed by a 
monomeric SPT homologue (for a review 
see (27)). 
Interestingly, deoxy-SA (m18:0; also 
referred to as “Spisulosine” or “ES-285”) 
has been isolated from the arctic clam 
Spisula polynyma as an investigational 
marine anticancer drug (28). It induces cell 
death in various breast cancer cell lines 
with an LD50 value in the lower µM range 
(29). It was shown that deoxy-SA 
stimulates an atypical apoptosis pathway 
without affecting JNK, Erk, or Akt 
signaling by activating protein kinase Cζ 
(29,30). 
In our work we demonstrated that the 
supplementation of the DSBs to neuronal 
DRG cultures is neurotoxic and interferes 
with the formation of the neurites in vitro. 
This effect was less pronounced for 
motoneurons, which is congruent with the 
pattern of pathology in HSAN1 where 
motoneurons are less affected. 
Interestingly, the presence of deoxy-SA 
not only impaired the number and length of 
newly formed neurites, but also induced 
the retraction of already formed neurites. 
Immune fluorescence microscopy 
indicated a disruption of the neurite 
cytoskeletal structure in the presence of 
deoxy-SA, where we observed a retraction 
of neurofilament although actin was still 
present along the full length of the neurites 
(Fig.5F). 
The observed neurotoxic effect was clearly 
detectable for deoxy-SA but less 
pronounced for deoxymethyl-SA. The fact 
that deoxymethyl-SA was not detected in 
the plasma of C133Y and V144D patients 
indicates that the presence of deoxymethyl-
SA is not essential for the pathogenesis of 
HSAN1. However, whether the m18:0 or 
one of its metabolic products, like deoxy-
dihydroceramide, deoxy-ceramide or 
deoxy-SO, is primarily responsible for the 
observed neurotoxic effect needs to be 
addressed in a subsequent study. 
The finding that elevated DSB levels are 
closely associated with HSAN1 also 
provides a new aspect in the diagnosis of 
HSAN1. Although HSAN1 is a rare 
disease its clinical appearance can be very 
heterogeneous and symptoms closely 
resemble the group of Charcot-Marie-
Tooth (CMT) neuropathies. CMT is the 
most commonly inherited neurological 
disorder, with an incidence of 30-40 in 
100,000. The lack of a blood biomarker for 
the diagnosis of CMT requires, classically, 
the verification of a clinically diagnosed 
CMT by sequencing. This often results in 
the extensive sequencing of many gene 
loci, especially in the case of a rare or 
spontaneous de novo mutation. The 
association of elevated plasma DSB levels 
with HSAN1 provides, for the first time, a 
blood marker that can be used, together 
with the clinical history, to confirm or 
exclude HSAN1 from other types of CMT. 
Furthermore, aberrations of SPT activity 
might be more frequently involved in 
peripheral neuropathies than is commonly 
believed. Very recently two new mutations 
in the SPTLC1 gene were reported to be 
associated with a sensory neuropathy (14) 
and further SPT mutations might be 
identified in the future. 
However, the exact pathomechanism by 
which the DSBs exert their neurotoxic 
activity is not yet fully clear. Our 
observations indicate that the DSBs act 
neurotoxically by disturbing neuronal 
cytoskeleton formation. In this context it is 
interesting that deoxy-SA was reported 
earlier to impair cytoskeleton formation by 
interfering with the Rho signaling cascade 
(28). Members of the Rho GTPase family 
have been shown to regulate various 
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aspects of intracellular actin and 
neurofilament dynamics, including cell 
polarization, axonal stabilization and 
growth cone formation (31). It is therefore 
conceivable that a destabilization of axonal 
structures or an impairment of growth cone 
formation would lead to a progressive 
degeneration of axons as seen in HSAN1. 
Another possibility could be that the DSBs 
have an inhibitory effect on one or several 
consecutive enzymes of the phospho- and 
glyco-sphingolipid pathway. A selective 
inhibition of one of these enzymes might 
reduce the levels of certain functional 
glycosphingolipids without significantly 
affecting total sphingolipid levels. An 
inhibitory effect on SO-kinase, for 
instance, would result in a reduction of 
SO-1P, which is a potent neurotrophic 
factor (32,33). Nevertheless, the findings 
presented here provide conclusive 
evidence that HSAN1 is closely associated 
with elevated DSB levels and that DSB 
levels, at concentrations similar to those 
found in the plasma of HSAN1 patients, 
exert pronounced neurotoxic effects on 
cultured sensory neurons. This suggests 
that the same neurotoxic activity is also 
responsible for the atrophy of sensory 
neurons in HSAN1 patients. 
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Figure Legends: 
 
Figure 1: 
A) De-novo sphingolipid synthesis pathway. 
De-novo ceramide synthesis involves several steps. Serine Palmitoyltransferase (SPT) 
catalyses the initial conjugation of palmitoyl-CoA with L-serine to form 3-keto-sphinganine 
which is subsequently reduced to sphinganine (SA). SA is acetylated by ceramide synthase 
(CerS) and desaturated by ceramide desaturase (DES) to form ceramide. The degradation 
pathway starts with the deacetylation of ceramide by ceramidase. The formed sphingosine 
(SO) is then phosphorylated by SO-Kinase and finally degraded to hexadecenal and 
phosphoethanolamine by the action of the sphingosine-1-phospate lyase (SO1P-lyase). 
B) HEK293 cells expressing the SPT-C133W mutant generate an unknown metabolite. 
HEK293 cells were transfected with either wildtype SPTLC1 or the SPTLC1-C133W mutant. 
De novo synthesis was blocked with Fumonisin B1 (FB1) for 24h. This causes an 
accumulation of sphinganine but also of other potential SPT products. The accumulated 
sphingoid bases were extracted and analyzed by HPLC. We observed a significant 
accumulation of SA in HEKL1 cells (black). SA accumulation was lower in HEKC133W cells 
(grey) which reflects the reduced activity of the mutant. In parallel we observed the 
appearance of a second, unknown peak (arrow). This peak appeared only in the presence of 
FB1 and was increased in cells expressing the C133W mutant. It was absent when SPT 
activity was blocked with myriocin. 
 
Figure 2: 
A) Products of the SPT reaction using serine, alanine or glycine as substrates. 
The conjugation of palmitoyl-CoA with alanine and glycine leads to the formation of the two 
deoxy-sphingoid bases (DSBs): 1-deoxy-sphinganine (m18:0) and 1-deoxymethyl-
sphinganine (m17:0). 
B) Chemical structure of the DSBs. 
An abbreviated nomenclature for sphingoid bases is used in this work. The number of 
hydroxyls are designated by “m” (mono-) and “d” (di-) followed by the number of carbons. 
The second number indicates the double bonds. For example: d18:0 stands for sphinganine 
and d18:1 for sphingosine. All shown metabolites were also found in the N-acetylated form.  
C) Accumulation of m18:0 and m17:0 in HEKC133W cells after supplementing the culture 
medium with alanine or glycine. HEKC133W cells were cultured using either standard medium 
(-) or medium that was supplemented with 10mM alanine (+ala) or 10mM glycine (+gly). De-
novo synthesis was blocked with FB1 for 24h and the accumulated lipids analyzed by LC-
MS. 
D) Accumulation of DSB in HEK cells expressing mutant forms of SPT. 
HEKempty, HEKL1, HEKC133W and HEKC133Y cells were treated with FB1 for 24h and the 
extracted lipids quantified by LC-MS. 
 
Figure 3: 
Accumulation of DSBs in EBV-transformed lymphoblasts of HSAN1 patients. 
A) The de-novo synthesis of DSBs was compared between in EBV-transformed lymphoblasts 
from twelve HSAN1 patients (all C133W carriers) and six healthy controls. Lymphoblasts 
were cultured for 24h in the presence of FB1, base extracted and analyzed by LC-MS. 
SO was not detected in the lymphoblasts. 
B) Sphingoid base levels in total lipid extracts of lymphoblasts from HSAN1 patients and 
healthy controls.  
Total cellular lipids were extracted and subjected to acid/base hydrolysis. The resulting free 
sphingoid bases were analyzed by LC-MS. No significant differences were seen in the total 
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amounts of SA or SO, whereas the concentration of m17:0, m17:1, m18:0 and m18:1 was 
significantly higher in the HSAN1 lymphoblasts compared to control cells.  
 
Figure 4: 
DSB plasma levels in HSAN1 patients and healthy controls A) Total plasma lipids from seven 
HSAN1 patients (C133W carriers) and three unrelated healthy controls were extracted and 
subjected to acid and base hydrolysis. B) The m17 sphingoid bases were only detected in the 
plasma of HSAN1 patients (P1-7). No m17 bases were found in control plasma (C1-7); 
Symbols: - not affected; + mildly affected, ++ moderately affected, +++ severely affected.  
C) Comparison of m18:0 and m18:1 levels in affected (P1-10) and unaffected members (C1-
10) of a C133Y family. All C133Y carriers showed significantly higher m18:0 and m18:1 
levels compared to family members which do not carry the mutation. No m17 sphingoid bases 
were detected in the plasma of the C133Y patients. 
D) m18:0 and m18:1 sphingoid bases were also significantly elevated in three carriers of a 
V144D mutation (P1-3) compared to four non carriers (C1-4) . No m17 sphingoid bases were 
detected in the V144D carriers.   
 
Figure 5: 
A) Effect of SA, m18:0 and m17:0 on cultured dorsal root ganglia (DRG) neurons. 
Dissociated sensory neurons were grown for 12 hours in control medium before the lipids 
were added for another 24 hours. The addition of SA (1µM) had no effect on neurite number 
and length compared to controls (cntr = BSA without lipids). In the presence of m18:0 (1µM) 
the cells showed a greatly reduced number of neurites. The addition of m17:0 (1µM) showed 
a similar but less pronounced effect.  
B) Quantitative analysis of the formed neurites in the presence of SA, m18:0 and m17:0. The 
presence of SA had no significant effect on neurite outgrowth whereas the presence of m18:0 
clearly reduced the number of neurites in a dose-dependent manner. A similar effect was 
observed for m17:0 whereby the presence of m17:0 mainly affected cells with two and more 
neurites. 
C) Effect of m18:0 on neurite formation in cultured motoneurons. Like sensory neurons we 
observed a significant reduction of neurite numbers in the presence of m18:0. However, this 
reduction was less pronounced at higher m18:0 concentrations in motoneurons than in sensory 
neurons. 
D) Distribution of neurite lengths in the presence of SA and deoxy-SA (m18:0) in sensory 
neurons. The distribution of neurite length was plotted as the percentage of neurons with 
neurites longer than a given length (y-axis) versus neurite length (x-axis) as introduced by 
Chang et al (21). The length was measured as total neurite length elaborated per neuron. 
Neurons were cultured for 12h prior the addition of the lipids (dashed line). The presence of 
SA (1 µM and 0.5 µM, blue) showed no reduction in the length of the formed neurites if 
compared to the control (BSA alone, dotted line). The presence of m18:0 significantly 
reduced neurite length in a dose-dependent manner (red lines). No difference to the control 
was seen with 0.1µM m18:0. In the presence of 0.5µM and 1µM m18:0 we observed a 
significant shortening of the neurites in a dose-dependent manner. At the highest m18:0 
concentrations tested (1µM) the neurites were even shorter than at the time the lipids were 
added (dashed line - neurite length prior the addition of the lipids). 
E) The presence of m18:0 induced neurite retraction. Cells were cultured for 24h prior the 
addition of the lipids (dashed line). In the presence of SA (1µM, blue line) the neurites 
continued growing although the growth rate was a little diminished in comparison to the 
control (pointed line). In contrast, the addition of m18:0 (1µM, red line) induced a significant 
retraction of the formed neurites. 
 15
F) This effect was confirmed by immune fluorescence microscopy of sensory neurons which 
were cultured in the presence of SA or m18:0 (1µM each, 24h). The SA treated cells looked 
healthy and showed a clear co-localization of actin (red) and neurofilament (green) over the 
whole length of the neurite (left panel). In contrast, m18:0 treated neurons showed a 
disruption of the neurite structure with a retraction of neurofilament and a disturbed actin-
neurofilament interaction (right panel). B – cell body; N – neurite; C – growth cone. 
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